NRx Pharmaceuticals Inc (NRXPW NASDAQ) stock market data APIs
$0.0865
-0.01(-11.6%)
as of December 5, 2025
Try our APIs with
free plan!
NRx Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Prev. Close
0.0865
Open
0.0772
High
0.0869
Low
0.0758
52 wk Range
0.05-0.5
Market Cap
715 M
Revenue
242 K
EPS
-0.4015
Beta
1.917
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NRx Pharmaceuticals Inc data using free add-ons & libraries
Get NRx Pharmaceuticals Inc Fundamental Data
NRx Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 242 K
- EBITDA: -15 199 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NRx Pharmaceuticals Inc News
New
NRx Pharmaceuticals outlines rapid clinic expansion and targets 6 or more locations by year-end 2025 amid new depression treatment advances
Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q3 2025 MANAGEMENT VIEW * Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of t...
NRx Pharmaceuticals outlines expanded fast track for NRX-100 and targets $750M ketamine market following balance sheet strengthening
Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q2 2025 MANAGEMENT VIEW * Jonathan C. Javitt, Co-Founder, Chief Scientist Officer, Chairman & Interim CEO, highlighted that NRx Pharmaceuticals i...
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team
Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the nat...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and its subsidiary, HOPE Therapeutics, Inc., are making a major move in mental health care with the acquisition of Kadima Neuropsychiatry Institute in La Jolla,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
